Saturday, November 19, 2022 11:29:48 AM
FeMike,
By Q2 the 3 year forward looking PE will be factored in along with buyout value of the platform based on development potential which newer legislation will impact by moving approved products forward faster. This will happen because institutions will be taking positions soon and providing coverage all while retail starts to really wake up and understand what is going on.
Once approval takes hold as a given after SNO coverage and commercialization readiness announcements by NWBO are published this will be accomplished. There won’t be a huge amount of time before institutions will gain access to establishing their positions as moves by NWBO to get up listed after announcements is also a given. One big buyer taking a position could launch this and NWBO hired 2 merger and acquisition/ uplisting folks to help ready them for this process.
I have no need to prove myself correct and respect your position. I’ll leave it at that; ). Best wishes.
By Q2 the 3 year forward looking PE will be factored in along with buyout value of the platform based on development potential which newer legislation will impact by moving approved products forward faster. This will happen because institutions will be taking positions soon and providing coverage all while retail starts to really wake up and understand what is going on.
Once approval takes hold as a given after SNO coverage and commercialization readiness announcements by NWBO are published this will be accomplished. There won’t be a huge amount of time before institutions will gain access to establishing their positions as moves by NWBO to get up listed after announcements is also a given. One big buyer taking a position could launch this and NWBO hired 2 merger and acquisition/ uplisting folks to help ready them for this process.
I have no need to prove myself correct and respect your position. I’ll leave it at that; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
